Handelsbanken Fonder’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$20.1M Buy
93,236
+10,510
+13% +$2.01M 0.06% 268
2026
Q1
$15.2M Sell
82,726
-1,502
-2% -$277K 0.05% 290
2025
Q4
$14.8M Sell
84,228
-15,088
-15% -$2.46M 0.04% 318
2025
Q3
$13.9M Buy
99,316
+1,715
+2% +$232K 0.04% 327
2025
Q2
$12.3M Buy
97,601
+17,347
+22% +$2.16M 0.04% 327
2025
Q1
$11M Sell
80,254
-1,681
-2% -$240K 0.05% 323
2024
Q4
$12.5M Buy
81,935
+13,433
+20% +$2.27M 0.05% 324
2024
Q3
$13.3M Buy
68,502
+1,296
+2% +$271K 0.05% 306
2024
Q2
$15.6M Buy
67,206
+3,146
+5% +$684K 0.07% 255
2024
Q1
$13.8M Buy
64,060
+6,527
+11% +$1.53M 0.06% 288
2023
Q4
$14.9M Sell
57,533
-18,231
-24% -$4.48M 0.07% 257
2023
Q3
$19.5M Buy
75,764
+974
+1% +$261K 0.11% 196
2023
Q2
$21.3M Buy
74,790
+5,555
+8% +$1.65M 0.11% 199
2023
Q1
$19.2M Buy
69,235
+3,013
+5% +$834K 0.11% 208
2022
Q4
$18.3M Sell
66,222
-12,177
-16% -$3.44M 0.12% 210
2022
Q3
$20.9M Sell
78,399
-1,586
-2% -$337K 0.14% 175
2022
Q2
$16.3M Buy
79,985
+37,671
+89% +$7.7M 0.11% 202
2022
Q1
$8.91M Sell
42,314
-23,372
-36% -$5.08M 0.05% 344
2021
Q4
$15.8M Sell
65,686
-21,897
-25% -$5.63M 0.08% 250
2021
Q3
$24.8M Sell
87,583
-8,757
-9% -$2.87M 0.13% 173
2021
Q2
$33.4M Buy
96,340
+9,134
+10% +$2.77M 0.17% 128
2021
Q1
$24.4M Buy
87,206
+25,525
+41% +$6.88M 0.14% 154
2020
Q4
$15.1M Sell
61,681
-2,698
-4% -$696K 0.09% 217
2020
Q3
$18.3M Sell
64,379
-844
-1% -$235K 0.13% 158
2020
Q2
$17.4M Buy
65,223
+25,851
+66% +$7.77M 0.15% 146
2020
Q1
$12.5M Sell
39,372
-4,500
-10% -$1.37M 0.27% 100
2019
Q4
$13M Buy
+43,872
New +$12.2M 0.23% 116
2017
Q1
Sell
-4,800
Closed -$1.36M 169
2016
Q4
$1.36M Sell
4,800
-3,700
-44% -$1.1M 0.04% 140
2016
Q3
$2.66M Sell
8,500
-1,530
-15% -$453K 0.08% 136
2016
Q2
$2.42M Sell
10,030
-5,000
-33% -$1.32M 0.1% 112
2016
Q1
$3.91M Sell
15,030
-24,943
-62% -$6.59M 0.17% 106
2015
Q4
$12.2M Buy
+39,973
New +$11.5M 0.24% 115

Other funds holding BIIB

Handelsbanken Fonder's BIIB Position: Q2 2026 in Review

Handelsbanken Fonder increased its Biogen (BIIB) stake by 13% in Q2 2026, buying an estimated $2.01M and bringing the position to 93,236 shares worth $20.1M. The position accounts for 0.06% of the portfolio, ranked #268.

Handelsbanken Fonder first reported a position in BIIB in Q4 2015 and has held it in 32 quarters since. The position peaked at $33.4M in Q2 2021. 679 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Handelsbanken Fonder held 93,236 shares of Biogen worth $20.1M as of Q2 2026.
  • Handelsbanken Fonder bought 10,510 Biogen shares in Q2 2026, an estimated $2.01M.
  • Biogen made up 0.06% of Handelsbanken Fonder's portfolio in Q2 2026, its #268 holding.
  • Handelsbanken Fonder first reported a position in Biogen in Q4 2015 and has held it in 32 quarters since.
  • Handelsbanken Fonder's Biogen position peaked at $33.4M in Q2 2021.
  • 679 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.